Literature DB >> 15745077

Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy.

Klaus E Mönkemüller1, Audrey J Lazenby, David H Lee, Robert Loudon, C Mel Wilcox.   

Abstract

Since the introduction of highly active antiretroviral therapy (HAART), the frequency of opportunistic disorders (ODs) of the gastrointestinal (GI) tract in human immunodeficiency virus (HIV)-infected patients has fallen dramatically. We have found, however, that despite the use of HAART, HIV-infected patients can still present with GI ODs. To evaluate the prevalence of GI ODs in HIV-infected patients on HAART who were undergoing endoscopic evaluation for GI-related symptoms. From January 1996 through February 2002, all HIV-infected patients undergoing GI endoscopy were prospectively identified; mucosal biopsies were obtained in a standardized fashion and histologic specimens were examined by a single GI pathologist. All the patients on HAART presenting with a GI OD are described. Results showed that 294 patients (88% men; mean age, 36.5 +/- 10 years; median CD4 lymphocyte count, 64 cells/microl; range, 1-884; median viral RNA level, 40,357 copies/ml; range, 0-7,721,715) underwent 401 upper and/or lower endoscopies during the study period. The use of HAART increased from 10% in early 1996 to 85% in 2002. Nevertheless we found that 27 patients (9%) presented with a GI OD despite HAART. Forty percent of the patients with a GI OD were noncompliant with HAART. We conclude that GI ODs can occur despite HAART and normal CD4 counts. The prevalence of GI ODs in HIV-infected patients taking HAART is 9%. The reasons for this are multifactorial and likely include noncompliance with medications, viral resistance to the drugs, and decreased drug bioavailability. Although the use of HAART has led to a decreased incidence of GI ODs in AIDS, the gastroenterologist evaluating these patients should not discard the possibility that the GI symptoms in HIV-infected patients taking HAART may be secondary to an OD, even when the CD4 count is normal and the viral load is low.

Entities:  

Mesh:

Year:  2005        PMID: 15745077     DOI: 10.1007/s10620-005-1587-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Impact of combination therapy for HIV infection on inpatient census.

Authors:  R A Torres; M Barr
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

2.  Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy.

Authors:  K E Mönkemüller; S A Call; A J Lazenby; C M Wilcox
Journal:  Am J Gastroenterol       Date:  2000-02       Impact factor: 10.864

3.  Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy.

Authors:  L Blum; C Pellet; F Agbalika; G Blanchard; P Morel; F Calvo; C Lebbé
Journal:  AIDS       Date:  1997-11       Impact factor: 4.177

4.  Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1.

Authors:  P Maggi; A M Larocca; M Quarto; G Serio; O Brandonisio; G Angarano; G Pastore
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-03       Impact factor: 3.267

5.  Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

Authors:  P T Nieuwkerk; M A Sprangers; D M Burger; R M Hoetelmans; P W Hugen; S A Danner; M E van Der Ende; M M Schneider; G Schrey; P L Meenhorst; H G Sprenger; R H Kauffmann; M Jambroes; M A Chesney; F de Wolf; J M Lange
Journal:  Arch Intern Med       Date:  2001-09-10

6.  Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

Authors:  J S Currier; P L Williams; S L Koletar; S E Cohn; R L Murphy; A E Heald; R Hafner; E L Bassily; H M Lederman; C Knirsch; C A Benson; H Valdez; J A Aberg; J A McCutchan
Journal:  Ann Intern Med       Date:  2000-10-03       Impact factor: 25.391

7.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

9.  Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.

Authors:  J A Bartlett; S L Benoit; V A Johnson; J B Quinn; G E Sepulveda; W C Ehmann; C Tsoukas; M A Fallon; P L Self; M Rubin
Journal:  Ann Intern Med       Date:  1996-08-01       Impact factor: 25.391

Review 10.  Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management.

Authors:  E N Janoff; P D Smith
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

View more
  14 in total

1.  Infectious diarrhoea in antiretroviral therapy-naive HIV/AIDS patients in Kenya.

Authors:  Jane W Wanyiri; Henry Kanyi; Samuel Maina; David E Wang; Paul Ngugi; Roberta O'Connor; Timothy Kamau; Tabitha Waithera; Gachuhi Kimani; Claire N Wamae; Mkaya Mwamburi; Honorine D Ward
Journal:  Trans R Soc Trop Med Hyg       Date:  2013-10       Impact factor: 2.184

2.  A patient carrying HIV.

Authors:  Bashir Adeela
Journal:  BMJ Case Rep       Date:  2009-05-17

3.  HIV-induced immunosuppression is associated with colonization of the proximal gut by environmental bacteria.

Authors:  Liying Yang; Michael A Poles; Gene S Fisch; Yingfei Ma; Carlos Nossa; Joan A Phelan; Zhiheng Pei
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

Review 4.  Gastrointestinal cytomegalovirus disease in the immunocompromised patient.

Authors:  Allison L Baroco; Edward C Oldfield
Journal:  Curr Gastroenterol Rep       Date:  2008-08

5.  CCAAT/enhancer binding protein beta is a major mediator of inflammation and viral replication in the gastrointestinal tract of simian immunodeficiency virus-infected rhesus macaques.

Authors:  Mahesh Mohan; Pyone P Aye; Juan T Borda; Xavier Alvarez; Andrew A Lackner
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 6.  Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients.

Authors:  Ana Luiza Werneck-Silva; Ivete Bedin Prado
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

7.  Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy.

Authors:  So Nishimura; Naoyoshi Nagata; Takuro Shimbo; Naoki Asayama; Junichi Akiyama; Norio Ohmagari; Hirohisa Yazaki; Shinichi Oka; Naomi Uemura
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

8.  Cytomegalovirus infection presenting as a colonic mass in a patient with acquired immunodeficiency syndrome.

Authors:  Dhyan Rajan; Robin Jacob; Sadat Rashid; Magdalene Vardaros; Anastasiya Pigal; Wondwossen Gebre; Kaleem Rizvon; Krishnaiyer Subramani; Umeko Takeshige; Paul Mustacchia
Journal:  Int Med Case Rep J       Date:  2011-07-22

9.  Wireless capsule endoscopy for the detection of small bowel diseases in HIV-1-infected patients.

Authors:  Mark Oette; A Stelzer; K Göbels; M Wettstein; A Sagir; T Feldt; D Häussinger
Journal:  Eur J Med Res       Date:  2009-05-14       Impact factor: 2.175

10.  Cytokine activation is predictive of mortality in Zambian patients with AIDS-related diarrhoea.

Authors:  Isaac Zulu; Ghaniah Hassan; Lungowe Njobvu R N; Winnie Dhaliwal; Sandie Sianongo; Paul Kelly
Journal:  BMC Infect Dis       Date:  2008-11-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.